NEWS
PUBLICATIONS
NEW MANUSCRIPT IN NATURE CHEMISTRY
We are excited to share that our manuscript describing small molecules that induce degradation of the dioxygenase IDO1, an important therapeutic target in immuno-oncology, has been published in Nature Chemistry. This work was a fantastic collaboration with the laboratories of Brenda Schulman and Herbert Waldmann and was led by former PostDoc Natalie Scholes.
January 2026
NEW MANUSCRIPT IN NATURE
We are delighted to announce the publication of our manuscript identifying kinase degradation as a common outcome of treatment with many kinase inhibitors. This tour‑de‑force study was led by former postdoctoral fellow Natalie Scholes and demonstrates that protein degradation frequently results from the supercharging of endogenous cellular degradation circuits.
November 2025
NEW REVIEW ARTICLE IN NATURE REVIEWS CANCER
We are very proud of our recent Review Article where, together with Valentina Spiteri and Alessio Ciulli, Matthias and Georg had the chance to summarize the status quo and current trends in targeted protein degradation, with a particular focus on applications in cancer research.
July 2025
NEW MANUSCRIPT IN NATURE COMMUNICATIONS
We are excited to share that our manuscript describing the mechanism of action of alkylamine-tethered degraders via the E3 ligase FBXO22 has been published in Nature Communications. This has been a fantastic collaboration with the research labs of Brenda Schulman and Steve Gygi and was led by by our PhD student Chrysanthi.
June 2024
PEOPLE
CONGRATS NATALIE!
With a heavy heart, we said goodbye to Natalie Scholes, a former Postdoc in the lab. While it is sad to see her leave, we couldn't be more excited and proud about her next move – starting an independent research lab at the Netherlands Cancer Institute!
December 2025
WINTER LAB MOVES TO AITHYRA
Georg has been selected by an international hiring committee headed by Maria Leptin to serve as the new Life Science director at AITHYRA, a new institute for Biomedical AI. As of September 2025, the Winter lab will fully relocate to Aithyra. Georg will remain affiliated with CeMM as an adjunct PI.
September 2025
FUNDING
ERC CONSOLIDATOR GRANT
We are very grateful for the ERC Consolidator Grant that has been awarded to the Winter lab! Through our longstanding interest in targeted protein degradation, we have developed a deep expertise in neomorphic pharmacology and proximity induction, which we can now deploy to directly rewire transcriptional circuits that are dysregulated or mutated in cancer. Over the next five years, we'll work very hard to provide proof of concept and deep mechanistic understanding for this therapeutic modality. Thanks to all current and former group members, mentors and colleagues who helped us to get into this position, we can't wait to get started!
December 2024
CANCER GRAND CHALLENGE
We are super excited to be part of team KOODAC, which is funded by the Cancer Grant Challenge initiative to identify and develop small-molecule degraders against oncoproteins that drive solid tumors in children.
March 2024
OUR RESEARCH INTERESTS
We work at the interface of chemical biology, proteostasis, and gene control. We aim to innovate novel chemical strategies that allow us to better understand fundamental principles of small-molecule action on transcription regulation and the ubiquitin-proteasome system.
Our current focus is on small-molecule degraders, which induce proximity between a target protein of interest and an E3 ubiquitin ligase to prompt ubiquitination and proteasomal degradation of the target protein. Towards a scalable, and rational strategy for ligand-induced destabilization of proteins, we developed heterobifunctional small-molecules by conjugating a phthalimide moiety to competitive antagonists of BET bromodomain proteins via a short, aliphatic linker. These compounds were the first PROTACs to show efficacy in vivo and prompted a widespread interest in the biopharmaceutical industry (Winter, Science 2015). Over the last years, research in our lab has been focused on developing methods to identify and mechanistically characterize monovalent and drug-like molecular glue degraders. This has led to the identification of degraders against otherwise undruggable proteins, such as Cyclin K (Mayor-Ruiz, Nature Chemical Biology 2020), has allowed us to functionally hijack a range of different E3 ligases, including DCAF11 and FBOX22 (Xue, Nature Communications, 2023; Kagiou, Nature Communications, 2024), and has also revealed a new modality in targeted protein degradation: intramolecular, bivalent glue degraders (Hsia, Hinterndorfer, Cowan, Nature 2024). Most recently, we have been interested in decoding how (and how often) inhibitors can induce target degradation (Scholes, Nature 2025).
In addition, we are keen to expand this concept towards other cellular functions, particularly focusing on small molecules that can functionally hijack transcriptional circuits, signaling or the DNA damage response.
In order to discover chemical neomorphs, small molecules that can endow proteins with novel functions to ultimately rewire cellular circuits, we frequently conduct phenotypic screens followed by mechanistic workup. We are thus excited about innovating and implementing cutting-edge technology that informs on principles of how small molecules interact with native biological systems. These studies are frequently driven by high-throughput and unbiased technologies such as quantitative proteomics, transcriptomics and particularly functional genomics. We are further excited to augment the interpretability of these large-scale datasets via artificial intelligence and machine learning methods. Connecting the derived insights with synthetic chemistry enables us to understand the mechanism of action of proteins, protein complexes or small molecules both on a holistic but also mechanistic level. In addition, we plan to leverage AI/ML to systematically move from phenotypic discovery to purposeful design of chemical neomorphs.
Our ultimate vision is that the fundamental insights that our work uncovers will contribute to therapeutic innovation that is built on the thesis of rewiring or (re-)programming of biological circuits.
multidisciplinary | technology enabled | mechanistically oriented | therapeutically inspired
OUR TEAM
Our team consists of research scientists, graduate students and postdoctoral researchers with a mixed background in molecular- and cell biology, chemistry and computational biology. Our lab is located at the Research Institute for Biomedical Artificial Intelligence
of the Austrian Academy of Sciences AITHYRA.
Carolina Caso
Carolina obtained her MSc in Pharmaceutical Sciences from La Sapienza, University of Rome. She pursued her doctoral studies at ETH Zürich in the group of Prof. Karl-Heinz Altmann, working on the total synthesis of natural products. In the Winter lab, she is focusing on the synthesis of libraries by means of direct-to-biology approach to identify new molecular glue degraders. .
Marko Cigler
Initially trained as a chemist in Zagreb, Marko completed his PhD in the lab of Kathrin Lang at the Technical University Munich where he worked on genetic code expansion. He joined the lab as a postdoctoral fellow in March 2020 to work on developing molecular glue degraders.
Jose Cisneros
Jose earned his PhD in medicinal chemistry in the group of Maria Luz Lopez-Rodriguez at Universidad Complutense in Madrid working in the synthesis of molecules involved in the regulation of the endocannabinoid system (ECS). He continued his work in the field of medicinal chemistry in the group of William Jorgensen at Yale University as a postdoctoral fellow and associate research scientist. During his time at Yale he was involved in the discovery of extraordinary potent anti-HIV and anti inflammatory agents. He joined the lab in 2020 as a research chemist to work in the synthesis of molecular glues and PROTACs. Away from chemistry he loves traveling, cooking, reading and playing piano.
Hanna Haller
Hannah joined the lab as Laboratory Technician in April 2024. She finished the Master program Molecular Biotechnology at FH Campus Wien and stayed at Karolinska Institutet, Stockholm (Sweden) for her Master research. Hannah has a great interest in cancer research and targeted protein degradation. Besides science she likes to explore new countries and cultures.
Matthias Hinterndorfer
Matthias did his PhD in Johannes Zuber’s lab at the Institute of Molecular Pathology Vienna, where he established temporally resolved CRISPR screens that led to the discovery of the vertebrate nuclear proteasome import pathway. In his work in the Winter lab, he is now looking to combine his interests in genetic screening and proteasome biology to elucidate the genetic determinants underlying chemically induced targeted protein degradation.
David Hoi
Initially trained as chemist, David completed his PhD in Molecular Biology at the Institute of Molecular Pathology in Vienna, where he studied novel targeted protein degradation strategies in pathogenic bacteria. He joined the Winter Lab in November 2023 aiming to develop chemical solutions to rewire transcriptional regulation in cancer. In his free time David is passionate about outdoor sports & tennis as well as cooking.
Chrysanthi Kagiou
Chrysanthi received her master's degree in Molecular Mechanisms of Disease at Radboud University in The Netherlands where she worked at Dr. Hobo's lab at Radboudumc, focusing on hematological malignancies. She completed her master thesis at Dr. Weigelin's group at Werner Siemens Imaging Center, in Germany studying cytotoxic T cells in melanoma. In September 2020, Chrysanthi joined Loizou Lab at the Institute of Cancer Research in Vienna, using advanced genome editing technologies to study cancer-associated mutations on DNA damage response genes. Chrysanthi joined Winter lab as a PhD student in June 2022, focusing on identifying novel molecular glue degraders in different cell states.
Lisa Kainacher
Lisa started as a PhD student in the Winter lab in autumn 2023. She studied Molecular Biotechnology in her BSc at the FH Campus Wien. For her undergraduate research, she joined the Christodoulou lab at University College London to investigate the structural underpinnings of protein misfolding. She then studied Molecular Medicine in her MSc at the University of Vienna. For her master research, she joined the Murray lab at the Max Planck Institute of Biochemistry in Munich where she worked on the complex role of tryptophan metabolism in human cancers and its association with ferroptotic cell death. In her PhD, Lisa will focus on the rewiring of transcriptional networks using small molecule libraries and chemical screens to exploit cancer vulnerabilities.
Katharina Kladnik
Katharina joined the Winter lab in 2022 as Technical Assistant. She completed her Masters studies in molecular biotechnology at the FH Campus Wien, where her interests focused around cancer and biopharmaceutical research. Besides working on targeted protein degradation, Katharina enjoys to play table tennis, travel the world and read.
Severin Lechner
Initially trained as biochemist, Severin completed his PhD in the lab of Bernhard Kuster at the Technical University of Munich, where he focused on (chemo-)proteomic drug target deconvolution methods. In the Winter lab, Severin is hunting for small molecules that allow to redirect transcription-regulating protein complexes.
Michael Lim
Michael earned his BSc (Honours) in Chemistry at the National University of Singapore where he gained an interest in chemical biology and interdisciplinary science. For his honours thesis, he worked in Ang Wee Han's lab on metal-ion enabled prodrug strategies for PROTACs. He joined the Winter lab in September 2024 to work on rewiring genome integrity. Apart from science, Michael enjoys good food and powerlifting.
Miquel Muñoz i Ordono
Initially trained as a biochemist in Barcelona, Miquel conducted his Master studies in Molecular biology at Utrecht University. After completing his undergraduate studies in Anna Obenauf’s lab at the Institute for Molecular Pathology in Vienna, where he studied the role of dendritic cells in immunotherapy-resistant melanoma, he joined the Winter lab in September 2020.
Caroline Schätz
Caroline studied Medical and Pharmaceutical Biotechnology at the IMC University of Applied Sciences in Krems. For her bachelor thesis she spent seven months at the Harvard Medical School in Boston working on tissue engineering using hypoimmunogenic stem cells. During this time, she also received the Marshall Plan Fellowship. For her master thesis she was working on the development of advanced organoid systems in the group of Christoph Bock in Vienna. In October 2022 Caroline joined the Winter lab as a PhD student, where her research efforts focus on dissecting drug feedback mechanisms using genetic screens as well as chemical screens in organoids.
Dmitri Segal
Dmitri completed his PhD in molecular genetics at the University of Toronto under the supervision of Dr. Mikko Taipale. There, he utilized high-throughput interaction proteomics and high-content immunofluorescent imaging to decipher functional differences between 14-3-3 paralogs and uncover their chaperone-like functions. Dmitri joined the Winter lab in June 2023 as a postdoctoral fellow to identify and characterize novel proximity inducing compounds that rewire the function of specific transcriptional/epigenetic regulators in cancer. In his free time, Dmitri enjoys the great Canadian pastime of playing hockey.
Georg Winter
Georg did his PhD at CeMM with Giulio Superti-Furga, working on elucidating the mechanism of action of anti-neoplastic drugs. He specialized on proteomics- as well as chemical genetics approaches to identify drug resistance mechanisms and synergistic drug combinations. He continued his training in chemical biology, working as a postdoctoral fellow with Dr. James Bradner the Dana Farber Cancer Institute/Harvard Medical School. Supported by an EMBO fellowship, he published the first paper reporting on in vivo target protein degradation (Winter et al., Science 2015). His postdoctoral work led to the foundation of C4 Therapeutics, now listed at the NASDAQ. He was recruited as a CeMM Principal Investigator in June 2016 where his research is focused on using the unique pharmacology of targeted protein degradation to understand and disrupt aberrant gene control circuits in cancer His interdisciplinary research lab is supported by several national and international grants and fellowships including an ERC Starting Grant. Moreover, Georg is a coordinator of a research partnership between CeMM and Pfizer. His work on molecular glue degraders led to the incorporation of Proxyen in May 2020. His work on PROTACs contributed to the incorporation of Solgate Therapeutics. Dr. Winter’s contribution to the field of targeted protein degradation was acknowledged via multiple prices and awards, including the Wilson S. Stone Memorial Award from MD Anderson (2021), the Eppendorf Award 2019 the Elisabeth Lutz Award of the Austrian Academy of Sciences.
OUR AlumNi
NATALIE SCHOLES – Postdoc, now independent PI at NKI Amsterdam
HANA IMRICHOVA – Postdoc and Computational Scientist
GARY TIN – Postdoc
FABIAN OFFENSPERGER - Postdoc
AMANDA NG – PhD student
MARK KUDADY – Research Intern
ALEX HANZL - PhD student
ANNA SCHREMPF - PhD student
VINCENTH BRENNSTEINER - Computational Scientist
ANDREA RUKAVINA – Technical assistant
SARAH DOBNER – Technical assistant
ELEONORA BARONE – Technical assistant
ELISA HAHN – Technical assistant
MARTIN JÄGER - PhD student
SOPHIE BAUER - Technical assistant and lab manager
CRISTINA MAYOR-RUIZ - Postdoc, now independent PI at IRB Barcelona
MATTHIAS BRAND - PhD student
DIOGO BORGES LIMA - Computational Scientist
SOMETH CHORN – Master student
OUR Publications
(lab members are highlighted in bold)
2026
Hennes E, Lucas B, Scholes NS, Cheng XF, Scott DC, Bischoff M, Reich K, Gasper R, Lucas M, Xu TT, Rossini S, Pulvermacher LM, Dötsch L, Imrichova H, Brause A, Führer S, Naredla KR, Sievers S, Kumar K, Janning P, Orabona C, Gersch M, Murray PJ, Schulman BA, Winter GE, Ziegler S, Waldmann H. Monovalent pseudo‑natural products supercharge degradation of IDO1 by its native E3 KLHDC3. Nature Chemical Biology 2026 Jan 7. doi: 10.1038/s41557-025-02021-5. Online ahead of print.
2025
Scholes NS, Bertoni M, Comajuncosa‑Creus A, Kladnik K, Guo X, Frommelt F, Hinterndorfer M, Razumkov H, Prokofeva P, Schwalm MP, Born F, Roehm S, Imrichova H, Santini BL, Barone E, Schätz C, Muñoz I Ordoño M, Lechner S, Rukavina A, Serrano I, Abele M, Koren A, Kubicek S, Knapp S, Gray NS, Superti‑Furga G, Kuster B, Shi Y, Aloy P, Winter GE. Inhibitors supercharge kinase turnover through native proteolytic circuits. Nature 2025 Nov 26. doi: 10.1038/s41586-025-09763-9. Online ahead of print.
Dikic I, Mayor‑Ruiz C, Winter GE, Koch K, Ciulli A, Thomä NH. Opportunities in proximity modulation: bridging academia and industry. Molecular Cell 2025 Aug 21;85(16):3012–3022. doi: 10.1016/j.molcel.2025.07.018.
Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE. Targeted protein degradation for cancer therapy. Nature Reviews Cancer 2025 Jul;25(7):493–516. doi: 10.1038/s41568-025-00817
Jochem M, Schrempf A, Wagner LM, Segal D, Cisneros J, Ng A, Winter GE, Krijgsveld J. Degradome analysis to identify direct protein substrates of small‑molecule degraders. Cell Chemical Biology 2025 Jan 16;32(1):192–200.e6. doi: 10.1016/j.chembiol.2024.10.007.
2024
Bond AG, Muñoz I Ordoño M, Bisbach CM, Craigon C, Makukhin N, Caine EA, Nagala M, Urh M, Winter GE, Riching KM, Ciulli A. Leveraging dual‑ligase recruitment to enhance protein degradation via a heterotrivalent proteolysis‑targeting chimera. Journal of the American Chemical Society 2024 Dec 11;146(49):33675–33711. doi: 10.1021/jacs.4c11556.
Winter GE. Extrapolating lessons from targeted protein degradation to other proximity‑inducing drugs. ACS Chemical Biology 2024 Oct 18;19(10):2089–2102. doi: 10.1021/acschembio.4c00191.
Kagiou C, Cisneros JA, Farnung J, Liwocha J, Offensperger F, Dong K, Yang K, Tin G, Horstmann CS, Hinterndorfer M, Paulo JA, Scholes NS, Sanchez Avila J, Fellner M, Andersch F, Hannich JT, Zuber J, Kubicek S, Gygi SP, Schulman BA, Winter GE. Alkylamine‑tethered molecules recruit FBXO22 for targeted protein degradation. Nature Communications2024 Jun 26;15(1):5409. doi: 10.1038/s41467-024-49739-3.
Cigler M, Imrichova H, Frommelt F, Caramelle L, Depta L, Rukavina A, Kagiou C, Hannich JT, Mayor‑Ruiz C, Superti‑Furga G, Sievers S, Forrester A, Laraia L, Waldmann H, Winter GE. Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting OSBP. Nature Chemical Biology 2025 Feb;21(2):193–202. doi: 10.1038/s41589-024-01614-4. Epub 2024 Jun 21.
He N, Depta L, Rossetti C, Caramelle L, Cigler M, Bryce‑Rogers HP, Michon M, Rafn Dan O, Hoock J, Barbier J, Gillet D, Forrester A, Winter GE, Laraia L. Inhibition of OSBP blocks retrograde trafficking by inducing partial Golgi degradation. Nature Chemical Biology 2025 Feb;21(2):203–214. doi: 10.1038/s41589-024-01653-x. Epub 2024 Jun 21.
Tin G, Cigler M, Hinterndorfer M, Dong KD, Imrichova H, Gygi SP, Winter GE. Discovery of a DCAF11‑dependent cyanoacrylamide‑containing covalent degrader of BET‑proteins. Bioorganic & Medicinal Chemistry Letters 2024 Jul 15;107:129779. doi: 10.1016/j.bmcl.2024.129779. Epub 2024 May 9.
Offensperger F, Tin G, Duran‑Frigola M, Hahn E, Dobner S, Ende CWA, Strohbach JW, Rukavina A, Brennsteiner V, Ogilvie K, Marella N, Kladnik K, Ciuffa R, Majmudar JD, Field SD, Bensimon A, Ferrari L, Ferrada E, Ng A, Zhang Z, Degliesposti G, Boeszoermenyi A, Martens S, Stanton R, Müller AC, Hannich JT, Hepworth D, Superti‑Furga G, Kubicek S, Schenone M, Winter GE. Large‑scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells. Science 2024 Apr 26;384(6694):eadk5864. doi: 10.1126/science.adk5864.
Hsia O, Hinterndorfer M, Cowan AD, Iso K, Ishida T, Sundaramoorthy R, Nakasone MA, Imrichova H, Schätz C, Rukavina A, Husnjak K, Wegner M, Correa‑Sáez A, Craigon C, Casement R, Maniaci C, Testa A, Kaulich M, Dikic I, Winter GE, Ciulli A. Targeted protein degradation via intramolecular bivalent glues. Nature 2024 Mar;627(8002):204–211. doi: 10.1038/s41586-024-07089-6. Epub 2024 Feb 21.
Barbosa BMG, Sfyaki A, Rafael S, José‑Duran F, Pous J, Sánchez‑Zarzalejo C, Perez‑Lopez C, Vilanova M, Cigler M, Gay M, Vilaseca M, Winter GE, Riera A, Mayor‑Ruiz C. Discovery and mechanistic elucidation of NQO1‑bioactivatable small molecules that overcome resistance to degraders. Angewandte Chemie International Edition 2024 Mar 18;63(12):e202316730. doi: 10.1002/anie.202316730. Epub 2024 Jan 18.
2023
Ng A, Offensperger F, Cisneros JA, Scholes NS, Malik M, Villanti L, Rukavina A, Ferrada E, Hannich JT, Koren A, Kubicek S, Superti‑Furga G, Winter GE. Discovery of molecular glue degraders via isogenic morphological profiling. ACS Chemical Biology 2023 Dec 15;18(12):2464–2473. doi: 10.1021/acschembio.3c00598. Epub 2023 Nov 21.
Xue G, Xie J, Hinterndorfer M, Cigler M, Dötsch L, Imrichova H, Lampe P, Cheng X, Adariani SR, Winter GE, Waldmann H. Discovery of a drug‑like, natural product‑inspired DCAF11 ligand chemotype. Nature Communications2023 Nov 30;14(1):7908. doi: 10.1038/s41467-023-43657-6.
Winter GE, Mayor‑Ruiz C. Proximity‑inducing pharmacology. Nature Chemical Biology 2024 Jan;20(1):13–14. doi: 10.1038/s41589-023-01492-2. Epub 17 November 2023.
Kozicka Z, Suchyta DJ, Focht V, Kempf G, Petzold G, Jentzsch M, Zou C, Di Genua C, Donovan KA, Coomar S, Cigler M, Mayor-Ruiz C, Schmid-Burgk JL, Häussinger D, Winter GE, Fischer ES, Słabicki M, Gillingham D, Ebert BL, Thomä NH. Design principles for cyclin K molecular glue degraders. Nature Chemical Biology 2023 Sep 7. doi: 10.1038/s41589-023-01409-z. Online ahead of print.
Enders L, Siklos M, Borggräfe J, Gaussmann S, Koren A, Malik M, Tomek T, Schuster M, Reiniš J, Hahn E, Rukavina A, Reicher A, Casteels T, Bock C, Winter GE, Hannich JT, Sattler M, Kubicek S. Pharmacological perturbation of the phase-separating protein SMNDC1. Nature Communications 2023 Aug 16;14(1):4504. doi: 10.1038/s41467-023-40124-0.
Dvorak V, Casiraghi A, Colas C, Koren A, Tomek T, Offensperger F, Rukavina A, Tin G, Hahn E, Dobner S, Frommelt F, Boeszoermenyi A, Bernada V, Hannich JT, Ecker GF, Winter GE, Kubicek S, Superti-Furga G. Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors. Cell Chemical Biology 2023 Aug 17;30(8):953-964.e9. doi: 10.1016/j.chembiol.2023.06.029. Epub 2023 Jul 28.
Nianzhe He, Laura Depta, Cecilia Rossetti, Marko Cigler, Marine Michon, Oliver Rafn Dan, Joseph Hoock, Julien Barbier, Daniel Gillet, Alison Forrester, Georg E. Winter, Luca Laraia. Selective inhibition of OSBP blocks retrograde trafficking by inducing partial Golgi degradation. biorxiv. April 2.
Marko Cigler, Hana Imrichova, Fabian Frommelt, Laura Depta, Andrea Rukavina, Chrysanthi Kagiou, J. Thomas Hannich, Cristina Mayor-Ruiz, Giulio Superti-Furga, Sonja Sievers, Luca Laraia, Herbert Waldmann# and Georg E. Winter#. Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting the oxysterol-binding protein OSBP. biorxiv. March 15
Gang Xue, Jianing Xie, Matthias Hinterndorfer, Marko Cigler, Hana Imrichova, Soheila Rezaei Adariani, Lara Dötsch, Georg E. Winter# and Herbert Waldmann#.Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype. chemrxiv. March 10.
Oliver Hsia, Matthias Hinterndorfer, Angus D. Cowan, Kentaro Iso, Tasuku Ishida , Ramasubramanian Sundaramoorthy , Mark A. Nakasone , Andrea Rukavina , Koraljka Husnjak , Martin Wegner, Alejandro Correa-Sáez, Conner Craigon, Chiara Maniaci, Andrea Testa, Manuel Kaulich, Ivan Dikic , Georg E. Winter# and Alessio Ciulli#. An intramolecular bivalent degrader glues an intrinsic BRD4-DCAF16 interaction. biorxiv. 2023 Feb 14.
Duran-Frigola M, Cigler M, Winter GE. Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence. J Am Chem Soc. Epub 2023 Jan 27.
Hanzl A, Barone E, Bauer S, Yue H, Nowak RP, Hahn E, Pankevich EV, Koren A, Kubicek S, Fischer ES, Winter GE. E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance. J Am Chem Soc. 2023 Jan 5.
Tin G, Winter GE. CIDE-stepping E3s. Nat Chem Biol. 2023 Jan;19(1):3-4.
2022
Schrempf A, Bernardo S, Arasa Verge EA, Ramirez Otero MA, Wilson J, Kirchhofer D, Timelthaler G, Ambros AM, Kaya A, Wieder M, Ecker GF, Winter GE, Costanzo V, Loizou JI. POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells. Cell Rep. 2022 Nov 29;41(9):111716.
Hanzl A, Casement R, Imrichova H, Hughes SJ, Barone E, Testa A, Bauer S, Wright J, Brand M, Ciulli A, Winter GE. Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders. Nat Chem Biol. 2022 Nov 3.
Peter B, Eisenwort G, Sadovnik I, Bauer K, Willmann M, Rülicke T, Berger D, Stefanzl G, Greiner G, Hoermann G, Keller A, Wolf D, Čulen M, Winter GE, Hoffmann T, Schiefer AI, Sperr WR, Zuber J, Mayer J, Valent P. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia. Am J Hematol. 2022 Sep;97(9):1215-1225.
2021
Müller S., Ackloo S, ..Winter GE, Workman P, Arrowsmith CH. Target 2035 - update on the quest for a probe for every protein. RSC Med Chem. 2021 Dec 3;13(1):13-21.
Zumer K, Maier KC, Farnung L, Jaeger MG, Rus P, Winter G, Cramer P. Two distinct mechanisms of RNA polymerase II elongation stimulation in vivo. Molecular Cell. 2021 Aug 5;81(15):3096-3109.e8.
Scholes NS, Mayor-Ruiz C, Winter GE. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches. Cell Chemical Biology, 2021 Mar 29:S2451-9456(21)00146-X. doi: 10.1016/j.chembiol.2021.03.007. Online ahead of print.
Kiely-Collins H, Winter GE, Bernardes GJL. The role of reversible and irreversible covalent chemistry in targeted protein degradation. Cell Chemical Biology, 2021 Mar 25: S2451-9456(21)00144-6. doi: 10.1016/j.chembiol.2021.03.005. Online ahead of print.
Jaeger MG, Winter GE. Fast-acting chemical tools to delineate causality in transcriptional control. Molecular Cell, 2021 Mar 4:S1097-2765(21)00125-8. doi: 10.1016/j.molcel.2021.02.015. Online ahead of print
Schick S, Grosche S, Kohl KE, Drpic D, Jaeger MG, Marella NC, Imrichova H, Lin JG, Hofstätter G, Schuster M, Rendeiro AF, Koren A, Petronczki M, Bock C, Müller AC, Winter GE, Kubicek S. Acute BAF perturbation causes immediate changes in chromatin accessibility. Nature Genetics, 2021 Feb 8. doi: 10.1038/s41588-021-00777-3.
2020
Mayor-Ruiz C, Bauer S, Brand M, Kozicka Z, Siklos M, Imrichova H, Kaltheuner IH, Hahn E, Seiler K, Koren A, Petzold G, Fellner M, Bock C, Müller AC, Zuber J, Geyer M, Thomä NH, Kubicek S, Winter GE. Rational discovery of molecular glue degraders via scalable chemical profiling. Nature Chemical Biology, 2020 Aug 3. doi: 10.1038/s41589-020-0594-x
Berger M, Knittl-Frank C, Bauer S, Winter GE, Maulide N. Application of Relay C-H Oxidation Logic to Polyhydroxylated Oleanane Triterpenoids. Chem 2020, https://doi.org/10.1016/j.chempr.2020.04.007
Jaeger MG, Schwalb B, Mackowiak SD, Velychko T, Hanzl A, Imrichova H, Brand M, Agerer B, Chorn S, Nabet B, Ferguson FM, Müller AC, Bergthaler A, Gray NS, Bradner JE, Bock C, Hnisz D, Cramer P, Winter GE. Selective Mediator dependence of cell-type-specifying transcription. Nature Genetics. 2020 Jun 1. doi: 10.1038/s41588-020-0635-0. Online ahead of print.
Bensimon A, Pizzagalli MD, Kartnig F, Dvorak V, Essletzbichler P, Winter GE, Superti-Furga G. Targeted degradation of SLC Transporters reveals amenability of multi-pass transmembrane proteins to ligand-induced proteolysis. Cell Chemical Biology. 2020 Apr 18. pii: S2451-9456(20)30117-3. doi: 10.1016/j.chembiol.2020.04.003.
Hanzl A, Winter GE. Targeted protein degradation: current and future challenges. Current Opinion in Chemical Biology. 2020 Jan 2;56:35-41. doi: 10.1016/j.cbpa.2019.11.012.
2010 - 2020
Erb MA, Scott TG, Li BE, Xie H, Paulk J, Seo HS, Souza A, Roberts JM, Dastjerdi S, Buckley DL, Sanjana NE, Shalem O, Nabet B, Zeid R, Offei-Addo NK, Dhe-Paganon S, Zhang F, Orkin SH, Winter GE, Bradner JE. Transcription control by the ENL YEATS domain in acute leukaemia. Nature. 2017 Mar 9;543(7644):270-274. PMID: 28241139
Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 2015. Science 348, 1376-81. PMID: 25999370
Where to find us.
AITHYRA
Research Institute for Biomedical Artificial Intelligence of the Austrian Academy of Sciences
Helmut-Qualtinger-Gasse 2, Stg. 2
A-1030 Vienna
How to contact us.
Interested in joining the lab?
Do you want to collaborate with us?
Do you need help with/access to tools we have generated?
Contact us: gwinter@aithyra.ac.at